XTL Biopharmaceuticals, Ltd. Completes the Acquisition of MinoGuard

HERZELIYA, Israel, November 30, 2011 /PRNewswire/ –

MinoGuard develops drugs to treat mental health diseases. MinoGuard’s lead drug for the treatment of schizophrenia patients is intended to improve the efficacy of existing treatments and minimize their side effects.

MinoGuard has…

Popularity: 1% [?]

Share this Post:
Digg Google Bookmarks reddit Mixx StumbleUpon Technorati Yahoo! Buzz DesignFloat Delicious BlinkList Furl

No Responses to “XTL Biopharmaceuticals, Ltd. Completes the Acquisition of MinoGuard”

Leave a Reply:

Name (required):
Mail (will not be published) (required):
Website:
Comment (required):
XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Get Adobe Flash playerPlugin by wpburn.com wordpress themes